Abstract
Migraine affects 15.3% of the US adult population, accounts for 3% of all annual US emergency room visits, and costs $13 billion to the US employers. The burden of migraine is high with younger adults, unemployed, and those with family income <$35,000/year. Recent years have seen several new drugs approved for migraine treatment. With high prevalence and cost associated with migraine, and the introduction of new migraine medications, the study objectives were to determine the changes in rates of non-adherence with migraine medicines and to identify the main reasons for non-adherence between 2019 and 2021.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
